Benchmark Has Buy on Synergetics USA
The Benchmark Company is out with a research report on Synergetics USA, Inc. (NASDAQ: SURG) and it has a Buy rating and a $7.50 price target on shares.
In a note to clients, The Benchmark Company writes, "Synergetics released full F4Q results and hosted a conference call. The quarter was in-line with last week's preannouncement. Revenue expanded 21% to $15.8 million and EPS rose 117% to $0.08. The business is progressing well toward its strategic objectives of improving operating efficiency and launching new products. We believe the stock is attractive based on a 12-month outlook but we have trimmed our F1Q EPS estimate to $0.06, from $0.08, to reflect delays in an R&D deal with Stryker (SYK: not covered) and a supply agreement with Alcon, which is now a division of Novartis (NVS: not covered)."
Shares of SURG closed at $5.90 yesterday.
